ZA200109691B - Mutual prodrugs of amlodipine and atorvastatin. - Google Patents

Mutual prodrugs of amlodipine and atorvastatin. Download PDF

Info

Publication number
ZA200109691B
ZA200109691B ZA200109691A ZA200109691A ZA200109691B ZA 200109691 B ZA200109691 B ZA 200109691B ZA 200109691 A ZA200109691 A ZA 200109691A ZA 200109691 A ZA200109691 A ZA 200109691A ZA 200109691 B ZA200109691 B ZA 200109691B
Authority
ZA
South Africa
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
mammal
pharmaceutical composition
Prior art date
Application number
ZA200109691A
Other languages
English (en)
Inventor
George Chang
Hamanaka Ernest Seiichi
Lamattina John Lawrence
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200109691B publication Critical patent/ZA200109691B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200109691A 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin. ZA200109691B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
ZA200109691B true ZA200109691B (en) 2002-11-26

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109691A ZA200109691B (en) 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin.

Country Status (41)

Country Link
US (1) US6486182B1 (da)
EP (1) EP1180102B9 (da)
JP (1) JP2003500487A (da)
KR (1) KR20020012247A (da)
CN (1) CN1352640A (da)
AP (1) AP2001002345A0 (da)
AR (1) AR022344A1 (da)
AT (1) ATE268764T1 (da)
AU (1) AU3313900A (da)
BG (1) BG106149A (da)
BR (1) BR0011006A (da)
CA (1) CA2375372C (da)
CO (1) CO5170457A1 (da)
CZ (1) CZ20014229A3 (da)
DE (1) DE60011424T2 (da)
DK (1) DK1180102T3 (da)
DZ (1) DZ3048A1 (da)
EA (1) EA200101130A1 (da)
EE (1) EE200100631A (da)
ES (1) ES2220426T3 (da)
GT (1) GT200000078A (da)
HK (1) HK1046282A1 (da)
HN (1) HN2000000075A (da)
HR (1) HRP20010856A2 (da)
HU (1) HUP0201433A2 (da)
IL (1) IL145947A0 (da)
IS (1) IS6135A (da)
MA (1) MA26736A1 (da)
MX (1) MXPA01012125A (da)
NO (1) NO20015756L (da)
OA (1) OA11950A (da)
PA (1) PA8495701A1 (da)
PE (1) PE20010169A1 (da)
PL (1) PL353483A1 (da)
PT (1) PT1180102E (da)
SK (1) SK16792001A3 (da)
SV (1) SV2002000082A (da)
TN (1) TNSN00113A1 (da)
TR (1) TR200103391T2 (da)
WO (1) WO2000073298A1 (da)
ZA (1) ZA200109691B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
JP4905738B2 (ja) 2007-10-10 2012-03-28 Ｎｏｋ株式会社 アキュムレータ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
EP1180102B1 (en) 2004-06-09
US6486182B1 (en) 2002-11-26
NO20015756L (no) 2002-01-24
KR20020012247A (ko) 2002-02-15
TNSN00113A1 (fr) 2005-11-10
DE60011424T2 (de) 2005-08-25
IS6135A (is) 2001-10-30
NO20015756D0 (no) 2001-11-26
EP1180102A1 (en) 2002-02-20
CN1352640A (zh) 2002-06-05
JP2003500487A (ja) 2003-01-07
SV2002000082A (es) 2002-02-05
EE200100631A (et) 2003-02-17
MXPA01012125A (es) 2002-06-04
CO5170457A1 (es) 2002-06-27
CA2375372A1 (en) 2000-12-07
BG106149A (bg) 2002-05-31
EA200101130A1 (ru) 2002-04-25
DE60011424D1 (de) 2004-07-15
CZ20014229A3 (cs) 2003-01-15
HK1046282A1 (zh) 2003-01-03
MA26736A1 (fr) 2004-12-20
SK16792001A3 (sk) 2003-03-04
AP2001002345A0 (en) 2001-12-31
WO2000073298A1 (en) 2000-12-07
PL353483A1 (en) 2003-11-17
PE20010169A1 (es) 2001-02-10
OA11950A (en) 2006-04-13
DZ3048A1 (fr) 2004-03-27
HN2000000075A (es) 2001-02-02
AU3313900A (en) 2000-12-18
IL145947A0 (en) 2002-07-25
HRP20010856A2 (en) 2002-12-31
PT1180102E (pt) 2004-08-31
DK1180102T3 (da) 2004-09-06
TR200103391T2 (tr) 2002-04-22
EP1180102B9 (en) 2005-03-02
HUP0201433A2 (en) 2002-08-28
GT200000078A (es) 2001-11-16
AR022344A1 (es) 2002-09-04
ES2220426T3 (es) 2004-12-16
PA8495701A1 (es) 2001-12-14
CA2375372C (en) 2007-01-09
BR0011006A (pt) 2002-02-19
ATE268764T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
ZA200109691B (en) Mutual prodrugs of amlodipine and atorvastatin.
ZA200109693B (en) Mutual salt of amlodipine and atorvastatin.
US6455574B1 (en) Therapeutic combination
CA2296726C (en) Combination therapy
ZA200400659B (en) Pharmaceutical compositions of amlodipine and atorvastatin.
US20040248948A1 (en) Combination therapy
US6737430B2 (en) Mutual prodrug of amlodipine and atorvastatin
CA2361288C (en) Mutual prodrug of amlodipine and atorvastatin